An Open-Label, Phase 1b Study to Evaluate Safety, Tolerability & Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects With High Risk Essential Thrombocythaemia Who Are Resistant to or Intolerant of Hydroxycarbamide Therapy
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Dencatistat (Primary)
- Indications Essential thrombocythaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Step Pharma
- 29 Jan 2025 New trial record